[Second-line chemotherapy with paclitaxel for ovarian cancer]. / Kiújult petefészekrák második vonalú kemoterápiás kezelése paclitaxellel.
Orv Hetil
; 142(42): 2299-301, 2001 Oct 21.
Article
em Hu
| MEDLINE
| ID: mdl-11760646
ABSTRACT
The authors summerize the results of second-line combination chemotherapy with paclitaxel (175 mg/m2, 3h) and carboplatin (AUC 5 mg/ml.min) in patients with recurrent epithelial ovarian cancer. The paclitaxel/carboplatin therapy was applied in 57 patients in 297 courses (median course/patient was 5, range 2, 12). Complete response (CR) was found in 3 patients (3/57 = 5%), however the tumorous process progressed after some time. The median progression free interval (PFI) was found to be 15 (range 3,130) weeks, with an average of 24.3 +/- 26.5 weeks. The authors conclude, that second-line paclitaxel combination therapy produces poorer results than the first-line treatment. These results, which are similar to the literature data have led to the agreement paclitaxel can be applied in ovarian cancer patients only in first-line chemotherapy in Hungary from the year 2000.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Paclitaxel
/
Antineoplásicos Fitogênicos
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
Hu
Revista:
Orv Hetil
Ano de publicação:
2001
Tipo de documento:
Article